TheraRadar
← Back
Data updated: Jun 28, 2026

VITARINE

Generics

VITARINE is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular.

1974
Since
23
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

VITARINE's Key Drugs

VITARINE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

VITARINE's Recent FDA Approvals

New NDA/BLA approvals for VITARINE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

VITARINE's Therapeutic Areas

VITARINE's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
1 drugs
Dermatology 33%
1 drugs
Cardiovascular 33%
1 drugs

VITARINE's Top Competitors

VITARINE's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

VITARINE Pipeline Snapshot

Active clinical trials for VITARINE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling